| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6011007 | NOVO NORDISK INC | Acylated insulin |
Feb, 2014
(10 years ago) | |
| US6869930 | NOVO NORDISK INC | Acylated insulin |
Feb, 2014
(10 years ago) | |
| US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
| US5750497 | NOVO NORDISK INC | Acylated insulin |
Jun, 2019
(4 years ago) | |
Levemir Innolet is owned by Novo Nordisk Inc.
Levemir Innolet contains Insulin Detemir Recombinant.
Levemir Innolet has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Levemir Innolet are:
- US6011007
- US6869930
- US5866538
- US5750497
Levemir Innolet was authorised for market use on 31 October, 2013.
Levemir Innolet is available in injectable;subcutaneous dosage forms.
Levemir Innolet can be used as levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus.
The generics of Levemir Innolet are possible to be released after 16 June, 2019.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-117) | May 18, 2015 |
| M(M-115) | Apr 06, 2015 |
Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus
Dosage: INJECTABLE;SUBCUTANEOUS
LEVEMIR INNOLET family patents
